WO1999026660A2 - Produit a activite proliferative utile pour traiter des cellules proliferatives - Google Patents

Produit a activite proliferative utile pour traiter des cellules proliferatives Download PDF

Info

Publication number
WO1999026660A2
WO1999026660A2 PCT/GB1998/003509 GB9803509W WO9926660A2 WO 1999026660 A2 WO1999026660 A2 WO 1999026660A2 GB 9803509 W GB9803509 W GB 9803509W WO 9926660 A2 WO9926660 A2 WO 9926660A2
Authority
WO
WIPO (PCT)
Prior art keywords
product
growth factor
active agent
biologically active
cytokine
Prior art date
Application number
PCT/GB1998/003509
Other languages
English (en)
Other versions
WO1999026660A3 (fr
Inventor
Christopher Ralph Franks
Ruggero Della Bitta
Original Assignee
Bioinnovation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinnovation Limited filed Critical Bioinnovation Limited
Priority to NZ504625A priority Critical patent/NZ504625A/xx
Priority to AU12499/99A priority patent/AU1249999A/en
Priority to EP98955771A priority patent/EP1032427A2/fr
Priority to JP2000521861A priority patent/JP2001523731A/ja
Priority to CA002311733A priority patent/CA2311733A1/fr
Publication of WO1999026660A2 publication Critical patent/WO1999026660A2/fr
Publication of WO1999026660A3 publication Critical patent/WO1999026660A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the use of proliferatively active compounds, especially cytokines or growth factors, as active vectors for pharmacologically active compounds, for example conventional drugs or genes.
  • cytokines and growth factors are both peptide hormones.
  • cytokines regulate the functional status of their target cells (i.e. they can stimulate or suppress both quantitatively and qualitatively), whilst growth factors are more focused on promotion, regulation and maintenance of proliferation and differentation, and the survival of their target cell lineages.
  • Both cytokines and growth factors recognise specific membrane receptors on their target cells, which are unique for that particular cytokine or growth factor. Each receptor, in turn, can express a dynamic avidity towards its specific cytokine or growth factor, based on physiological and/or pathological conditions. These receptors can be categorised as low, medium, or high affinity. Most important of all, high affinity receptors only recognise, capture, and internalise their related cytokine or growth factor. These receptors and their ligands are discussed in more detail below with reference to cytokines.
  • Cytokines are a group of molecules, other than antibodies, which are produced by lymphocytes and involved in signalling between cells of the immune system, for the purpose of stimulating or suppressing cell function. Cytokines often mediate their action by specific receptors expressed on target cells. Cytokines are glycosylated or non-glycosylated polypeptides and can be secreted by both T-cells and B- cells, though T-cells are assumed to be the major source in cell-mediated responses. Complications in the study of cytokines have arisen from the fact that in vivo no cytokine ever operates in isolation. This is illustrated by the observation that many cytokine actions are synergistic. Important cytokines include interleukins (ILs), tumour necrosis factors (TNFs) and interferons (IFNs). In addition, various colony stimulating factors (CSFs) are secreted by myeloerythroid cells.
  • ILs interleukins
  • TNFs tumour necrosis factors
  • cytokine receptor super family CKR-SF
  • haemopoietic receptor super family CKR-SF
  • IFNR-SF interferon receptor super family
  • Type II (Ref 1).
  • the term "super family” should be used only to describe proteins with amino acid sequence homology of 50% or less. Proteins, with amino acid sequence homology of greater than 50%, are designated by the term "family”.
  • a domain is a sequence or segment of a protein which forms a discrete structural unit, able to capture and/or convert specific signals.
  • the domains of interest are the extra-cellular regions
  • CKR-SF haematopoietic receptor super family
  • these sites have low (e.g. 1-lOnM) or high (e.g. at least lpM and more usually 10-100pM) affinity to a given ligand (cytokine or growth factor).
  • ligand cytokine or growth factor
  • additional sub-units have been identified which are required for high affinity receptor expression. These sub-units (also referred to as affinity convertors or convertor chains) are often expressed on the cell surface after a given activatory or inhibitory stimulus is applied through a receptor ligand.
  • T-cells To mediate immune responses, T-cells must change from a resting to an activated state. T-cells stimulated by foreign antigens enter a program of cellular activation leading to de novo synthesis of IL-2. Resting T-cells do not express high affinity receptors but these are rapidly expressed after activation. Interaction of IL-2 with its induced cellular receptors triggers cellular proliferation culminating in the emergence of effector T-cells that are required for the full expression of immune responses.
  • High affinity receptors therefore include those with an affinity constant of 10 " '°M or less, and, more particularly, those with an affinity constant of 10 " ⁇ M or less.
  • Representative high affinity receptors include those with affinity constants of between 10 " and 10 "1 M.
  • IL-2 interleukin-2
  • three forms of receptor for interleukin-2 (IL-2) can be distinguished on the basis of their affinity for IL-2 with IL-2 binding affinities of 10 " "M (high affinity), 10 "9 M (intermediate affinity) and 10 "8 M (low affinity) (Refs 1-4).
  • IL-2 receptors are well described in the prior arts (Refs 5 & 6).
  • TNF- ⁇ has been described as having two isoform receptors with high affinity on the target cells for TNF.
  • M-GSF macrophage colony stimulating factor
  • the high affinity receptor is a 150 Kda glycoprotein (Ref 8).
  • IFN- ⁇ has a 90 KDa glycoprotein as a high affinity receptor.
  • a different receptor present on activated lymphocytes, macrophages, endothelial cells and fibroblasts has been recognised as the high affinity receptor of IFN- ⁇ and IFN- ⁇ (Ref
  • FGF fibroblastic growth factor
  • a high affinity receptor which is a 140 KDa glycoprotein on mesodermic and neuroectodermic lineage cells, such as activated fibroblasts, macrophages, endothelial cells, chondrocytes, astrocytes, glioma cells, hepatocytes, epithelial cells, neurones, ovarian cells, pituitary cells, and keratinocytes.
  • the pharmacological properties of FGF are primarily related to angiogenesis, ovarian steroidogenesis, ostoblast activation, and nerve growth (during the foetal phase) (Ref 10).
  • IGF insulin-like growth factor
  • IGF has a high affinity receptor on eterotetrameric complex present in different tissues and in mammary adenocarcinoma (Ref 11 ).
  • TGF ⁇ Transforming Growth Factor ⁇
  • IGF Transforming Growth Factor ⁇
  • TGF ⁇ is a non-glycosylated homodymeric protein secreted by fibroblasts, epithelial cells, platelets, astrocytes, monocytes, bone cells, and glioblastoma cells.
  • the physiological target cells are primarily fibroblasts, osteoblasts, neutrophils, hematopoietic progenitors, T/B lymphocytes, and a range of tumor cells.
  • the cytokine interacts with a high affinity receptor, expressed by the target cells, in response to paracrine microenvironmental stimulation, located on the cell surface of the above cells. These are type 1 or type 2 receptors (55 and 80 Kda), and are able to bind to TGF ⁇ l, 2, and 3.
  • GM-CSF granulocyte/macrophage colony stimulating factor
  • SCF stem cell factor
  • G-CSF granulocyte colony stimulating factor
  • G-CSF also has a high affinity receptor present, but only in multipotent cells in the bone marrow.
  • EPO erythropoietin
  • IL-6 (interleukin-6) has an ⁇ -/ ⁇ - high affinity receptor.
  • the alpha chain binds IL-6 with low affinity and exists in a soluble form.
  • the beta chain is a 130 KDa protein which simultaneously binds IL-6/IL-6r, becoming a trimeric complex which initiates target cell stimulation.
  • IL-6 high affinity receptor induction following specific stimuli, is primarily positioned on activated cells such as T/B lymphocytes, fibroblasts, myeloid precursors, neurones, keratinocytes, and hepatocytes. In addition, multiple myeloma cells produce
  • IL-6 and express IL-6 receptors working as an autocrine cancer growth factor, inducing at the same time osteoclastogenesis (bone lytic lesions).
  • osteoclastogenesis bone lytic lesions.
  • IL-6 from stromal cells can also be involved in bone metastatic lesions through different tumour histotypes.
  • Radio-labelled studies were carried out to evaluate the in vivo distribution of very-low dose radiolabelled IL-2, when administered intravenously (iv) in pathological conditions in which naturally activated lymphocytes are the major factor responsible for the pathogenesis of a disease (Refs 13, 14).
  • the models tested were autoimmune diseases, such as autoimmune diabetes mellitus (in diabetes-prone rats), patients with newly diagnosed autoimmune Type I diabetes, patients with newly diagnosed autoimmune thyroiditis, and patients with newly diagnosed chronic inflammatory diseases of the bowel (Coeliac disease and Crohn's disease) (Refs 14, 15, 16).
  • labelled IL-2 is detected and retained only in those sites (organs) which are the target of the particular autoimmune pathological condition, and NOT in normal organs (i.e. in organs unaffected by the immune system attack).
  • Labelled IL-2 retains its capacity for binding to the IL-2 receptor on activated lymphocytes in vitro.
  • a fusion protein of an IL-2 sequence and a diphtheria toxin sequence has been used to selectively target cells bearing the high affinity IL-2 receptor.
  • the approach taken was to construct a diphtheria toxin-related IL-2 fusion gene that encodes a recombinant toxin in which the diphtheria toxin receptor binding domain is replaced with amino acids 2-133 of IL-2.
  • the chimeric IL-2-toxin was expressed in recombinant strains of E. coll K-12 and shown to selectively inhibit protein synthesis in only those T-cell lines which express the high affinity IL-2 receptor (Ref 22).
  • IL-2-PE40 chimeric protein containing sequences of Pseudomonas exotoxin (PE) and IL-2 was able to provide a lymphokine-mediated method of delivering the toxin to IL-2r-expressing cells (Ref 6).
  • the chimeric IL-2-diphtheria toxin does not contain a biologically active IL-2 sequence but only the receptor-binding sequence.
  • the protein has entered Phase III trials for the treatment of cutaneous T cell lymphoma (Scrip, January 13, 1995 and New Scientist, November 1, 1997). Blast leukemic cells usually bear only the low/intermediate affinity isoforms of the IL-2 receptor (although a tiny minority of the receptors will be high affinity receptors) and the therapy therefore involves high dose i.v. administration of the protein to destroy neoplastic cells bearing any IL-2 receptor. Such therapy is liable to show high toxicity. Moreover, as a chimeric protein, the compound is liable to be immunogenetic.
  • the IL-2-PE40 was found to have only limited activity against human T-cells and alternative molecules have therefore been constructed in a search for a more active agent (Ref 6).
  • WO 92/20364 describes hybrid molecules containing a first portion which is a molecule capable of decreasing cell viability (especially a cytotoxin) and a second portion which is a molecule capable of specifically binding to a cytokine receptor (especially all or a binding portion of a cytokine).
  • the second portion targets the first portion to the cytokine receptor and is exemplified as IL-2.
  • the IL-2 portion preferably lacks IL-2 activity because the molecules will then prevent proliferation of the target cells.
  • the present invention is based in one aspect on an insight that a medicament which contains an active promoter of proliferation, for example an active IL-2, can beneficially be used to deliver pharmacologically desirable species to cells whose proliferation is not desired.
  • some medicaments of the invention control or inhibit proliferation using a molecule which contains an active promoter of proliferation.
  • Preferred embodiments are based on an appreciation that, by using the high affinity of receptor super families, it is possible to drive drugs or genetic material, for example, into specific cell lineages which are predominantly responsible for many clinical events.
  • the present invention provides a composition of matter (product, e.g. compound) comprising a proliferatively active moiety linked to a biologically active agent which agent preferentially or selectively affects proliferating cells.
  • a biologically active agent linked to a cytokine or growth factor which has a high affinity receptor or is a molecule functionally equivalent to such a cytokine or growth factor.
  • the link between the two domains of the product is normally capable of being broken under intracellular conditions, for example by acid hydrolysis.
  • the proliferatively active moiety retains its functional activity, which can come into play once the product targets its receptor.
  • the proliferatively active moiety binds to the receptor and is then internalised by the cell, so that each active domain of the product (the proliferatively active moiety and the biologically active agent) can perform its respective function. It is contemplated that the two domains of the product will separate intracellularly in commercially viable products, but this is not essential and the invention is not restricted to products which are intracellularly cleavable.
  • the events which follow binding of the proliferatively active moiety to the receptor typically include internalisation of the product (typically a fusion compound) into the cytosol (by the endosome pathway), endosome acidification
  • the receptor domain and the proliferatively active domain (normally a cytokine or growth factor domain) retain their functional integrity, the proliferatively active domain (cytokine or growth factor) will trigger cell activation/division through DNA interaction (G2-M phase enrichment).
  • the invention provides products in which an active moiety is linked, usually but not necessarily by a covalent bond cleavable intracellularly, with a proliferatively active moiety, i.e. a moiety which causes cellular proliferation.
  • a proliferatively active moiety i.e. a moiety which causes cellular proliferation.
  • the proliferatively active moiety has a high affinity receptor and the products can be administered at very low dosages such that the only cells which are targeted are those presenting a high affinity receptor to the proliferatively active moiety (normally a cytokine or growth factor).
  • the product is internalised into the target cells, where the biologically active moiety is normally separated from the proliferatively active moiety.
  • the invention also includes in another aspect a method of treating by prophylaxis or therapy a disease or disorder involving cells bearing a high affinity receptor for, in particular, a cytokine or growth factor, comprising administering to a patient an effective amount of a product comprising an agent which is biologically active when in said cells and is linked to said cytokine or growth factor; such products and preparations containing them form a further aspect of the invention.
  • a product of the invention for use as a pharmaceutical, especially in internalising the biologically active agent into a cell having a- high affinity receptor for the proliferatively active agent, cytokine or growth factor of the product.
  • Another aspect of the invention resides in the use of a product of the invention for the manufacture of a medicament for internalising the biologically active agent into a cell having a high affinity receptor for the proliferatively active agent, cytokine or growth factor of the product and optionally for stimulating lymphocyte proliferation.
  • the biologically active agent is in one preferred class of products a substance which is effective to kill or inactivate proliferating cells, such that the activities of the physiologically active agent and the proliferatively active agent are complementary in their activity.
  • a biologically active agent may be an antiproliferative drug, for example an antiblastic agent or a chemotherapeutic agent which, for example, interferes with DNA replication.
  • the proliferatively active agent in one class of products promotes lymphocyte replication.
  • a construct of IL-2 and antisense DNA/RNA designed to block a retrovirus gene obtains the following effects:
  • the replicative stimulus given by the IL-2 stimulates also replication of the viral genome, resulting in stronger inhibitory activity by the antisense DNA/RNA;
  • the product is a combination of two existing moieties (or of moieties functionally equivalent thereto), each of which retains its function and, optionally, its entire structure (except at any covalent linkage site to the other moiety)
  • the product can be produced by chemical combination of the two moieties, for example using standard techniques
  • the product can be administered at exceedingly low dosages, so that little or no systemic toxicity results.
  • the growth factor/cytokine stimulates the immune system and the active moiety induces a therapeutic effect • biodistribution is predictable and good
  • the biologically active agent (normally a medicament) is linked to a proliferatively active moiety.
  • a proliferatively active moiety Unlike prior art chimeric proteins containing solely the receptor-binding domain of IL-2, therefore, these products induce cellular proliferation, enabling anti- proliferative drugs to be highly effective, even at ultra-low doses in the case of proliferatively active moieties with high affinity receptors.
  • the invention therefore enables low systemic toxicity to be achieved.
  • An additional benefit at least in the case of IL-2 is that IL-2 induces expression of the high affinity IL-2 receptor when the relevant antigen is present.
  • the cytokine may be an interleukin, for example a TNF, for example an M-CSF; an IFN, for example an FGF; an IFG; a TGF, for example a GM-CSF; an SCF; a G-GSF; or an EPO.
  • a TNF for example an M-CSF
  • an IFN for example an FGF
  • an IFG for example an IGF
  • a TGF for example a GM-CSF
  • SCF for example a G-GSF
  • G-GSF G-GSF
  • EPO EPO
  • the cytokine is preferably a human cytokine.
  • the growth factor may be a haematopoietic or lymphopoietic growth factor. They are a family of glycoprotein hormones which regulate survival, proliferation, and differentiation of progenitor cells, in addition to impacting on some functional activities of mature lymphohaematological cells.
  • Suitable growth factors include:
  • Erythropoietin Epo
  • GM-CSF GM-CSF
  • SCF Stetem cell factor
  • Multi-CSF also known as Interleukin-3
  • M-CSF M-CSF
  • E-CSF or Interleukin-5
  • IGF-1 Insulin-like growth factor
  • PDGF Platinum-derived growth factor
  • TGF beta2 Transforming growth factor -beta2
  • Cytokines or growth factors may be- native or a mutein representing the native molecule modified by one or more amino acid alterations (deletions, additions or substitutions).
  • Such muteins, usable in the present invention possess the biological activity of the native protein, in the sense of having both functional affinity for the receptor (and in one class of embodiments functional affinity for the high affinity receptor) and a capability of forming, with the receptor, a product internalised by the cell presenting the receptor.
  • Cytokines and growth factors are preferably recombinant molecules, but may be produced by cultivating cytokines or growth factor producing cell lines, for example peripheral blood lymphocytes.
  • the products comprise a biologically active compound linked to a molecule which is functional to have a high affinity with a cytokine or growth factor high affinity receptor, and to form a complex with such a receptor which is internalised by the cell presenting the receptor.
  • the molecule may be a native or mutein cytokine, or a fragment thereof.
  • the molecule may be a native or mutein growth factor, or a fragment thereof.
  • IL-2 is a lymphokine which is produced by normal peripheral blood lymphocytes, and induces proliferation of antigen or mitogen stimulated T-cells after exposure to plant lectins, antigens, or other stimuli.
  • IL-2 was first described by Morgan, D A., at el, Science (1976), 193: 1007-1008. Then called T-cell growth factor because of its ability to induce proliferation of stimulated T lymphocytes, it is now recognised that, in addition to its growth factor properties, it modulates a variety of functions of immune system cells in vitro and in vivo, and has been renamed interleukin-2 (IL-2).
  • Interleukin-2 may be made by cultivating human peripheral blood lymphocytes (PBL), as described, for example, in US Patent No. 4,401,756.
  • PBL peripheral blood lymphocytes
  • the IL-2 may be recombinant. Taniguchi, T. et al., Nature (1983), 302:305-310 and Devos, R., Nucleic Acids Research (1983), 1 1 :4307-4323 have reported cloning the human IL-2 gene and expressing it in micro-organisms.
  • US Patent No. 4,518,584 describes and claims muteins of IL-2 in which the cysteine normally occurring at position 125 of the wild-type or native molecule has been replaced with a neutral amino acid, such as serine or alanine.
  • An oxidation-resistant mutein of IL-2 which is biologically active may be prepared wherein each methionine residue of the protein from which the mutein is derived is replaced with a conservative amino acid such as alanine; the methionine residue(s) is/are susceptible to chloramine T or peroxide oxidation.
  • These IL-2 muteins possess the biological activity of native IL-2.
  • 4,530,787 and 4,569,790 disclose and claim methods for purifying recombinant native IL-2 and muteins thereof, as well as purified forms of IL-2.
  • the aforesaid US patents are included herein by reference.
  • the IL-2 mutein desala,-IL-2 ser 125 is available commercially from Chiron B.V. of Amsterdam, Netherlands under the trade mark Proleukin®.
  • the biologically active agent may in principle be any compound effective to act on the functioning of a cell in which the active agent is internalised. However it is normally a species which acts selectively or preferentially on the proliferating cell, and in such embodiments is not for example a polypeptide cytotoxin such as pseudomonas exotoxin or diphtheria toxin.
  • the active agent is an immunosuppressant, for example a known immunosuppressive drug.
  • the active compound comprises an antisense nucleotide sequence, e.g. an anti-oncogene sequence; in other embodiments the active agent is an enzyme inhibitor, e.g. an inhibitor of a viral reverse transcriptase.
  • the active agent may be an antitumour or other antitumour agent.
  • the active agent comprises a radioactive isotope.
  • Particularly preferred are products comprising a biologically active agent linked to a cytokine or growth factor or to a molecule functionally equivalent thereto, the biologically active agent being selected from the group consisting of antiproliferative drugs, compounds which interfere with nucleotide synthesis, radioisotopes, gene sequences and antisense nucleotide sequences, and the cytokine or growth factor having target cells capable of presenting a high affinity receptor therefor.
  • the biologically active agent agent is suitably an immunosuppressant, an enzyme inhibitor or an anti-cancer drug.
  • these particularly preferred products include those in which the biologically active agent is cyclosporin, FKK 506, thalidomide, a dihydrofolate reductase inhibitor, an antiblastic drug, a platinum coordination complex, a vinca alkaloid, a purine analogue, a pyrimidine analogue, a corticosteroid, a viral reverse transcriptase inhibitor or an antisense nucleotide sequence.
  • the biologically active agent is cyclosporin, FKK 506, thalidomide, a dihydrofolate reductase inhibitor, an antiblastic drug, a platinum coordination complex, a vinca alkaloid, a purine analogue, a pyrimidine analogue, a corticosteroid, a viral reverse transcriptase inhibitor or an antisense nucleotide sequence.
  • a specific class of products are those in which the biologically active agent is cyclosporin, a vinca alkaloid, FKK 506, thalidomide, methotrexate, azathioprine, cyclophosphamide, actinomycin D, daunombicin, doxombicin, bleomycin, a rhenium radioisotope, an yttrium radioisotope, 3'-azido-3'deoxythymidine, an antisense nucleotide sequence that binds to a viral nucleotide sequence or an anti-oncogene nucleotide sequence.
  • the active agent is not a pro-drug; of course, pro-drugs are included in the invention if the metabolism required for their conversion to the active drug is located in the cytoplasm of the target cell.
  • the products of the invention preferably act only on cells presenting a high affinity receptor for the cytokine or growth factor, which are typically lymphocytes or other cells involved in the immune response.
  • the action of a product of the invention on its target cells depends on the function of the active agent.
  • the biologically active agent is preferably not a polypeptide. Preferably it is a monomeric organic compound.
  • the biologically active agent may comprise a metal.
  • the biologically active agent is an organic compound
  • the active agent is normally covalently linked to the proliferatively active moiety (especially cytokine or growth factor).
  • the products of the invention are often molecules.
  • Metal-containing products normally comprise an organometallic complex consisting of an organic member which is covalently bonded to the proliferatively active moiety.
  • the molecular ratio of the active agen proliferatively active moiety in the products of the invention is not critical.
  • the invention includes ratios of 1 : 1 or less but in some embodiments the ratio is greater than 1 : 1, e.g. 1 :1000 or more, i.e. a plurality of active agent molecules/atoms may be bound to each proliferatively active moiety
  • Cyclosporine a second generation immunosuppressive, has a highly selective capacity to inhibit activation of T-cells (Ref l7).
  • Cyclosporine Unlike the first generation immunosuppressants, such as azathioprine, methotrexate, and cyclophosphamide, therapeutic concentrations of Cyclosporine do not cause myelotoxicity. Cyclosporine inhibits the early cellular response to antigenic and regulatory stimuli, primarily by targeting T- lymphocytes.
  • Cyclosporine induces a rapid and profound inhibition of IL-2 production by T-cells, and causes a general reduction in the production and release of other lymphokines in response to the antigenic stimulus. At high intracellular concentrations, Cyclosporine inhibits expression of receptors for IL-2.
  • Cyclosporine and particularly Cyclosporine-A (Cs-A) is therefore widely used to sustain renal, hepatic, and cardiac transplants.
  • Cs-A Cyclosporine-A
  • the use of Cs-A in autoimmune diseases is less common, due to the side effects (both acute and delayed), which are linked to the therapeutic range of the systemic dose used, and the duration of the therapy.
  • Cyclosporine The major clinical toxicity of Cyclosporine is renal, and usually occurs in 25%-75% of patients treated. The toxicity is dose-related, and is irreversible in some patients. The reduction of the Cyclosporinemia, within the therapeutic range, results in a worsening of the underlying disease (graft rejection). Other systemic side-effects include hypertension, neurological toxicity, and an increased incidence of infections due to systemic immunosuppression. This general reduction in immunocompetence also increases the incidence of malignancies in transplanted patients.
  • a preferred pharmacological product comprising chemically linked IL-2 and Cyclosporine (Cs-A or analogues in the same class of drugs) provides ultra specific immunosuppression; that is, a new third generation immunosuppressive approach.
  • the system maintains the immunosuppressive pharmacological characteristics of Cyclosporine (Cs-A or analogues) on lymphocytes, but the action is selectively - directed only to those lymphocytes which can internalise the complex (IL-2/Cs) (i.e. lymphocytes bearing high-affinity receptors for IL-2), which are naturally activated in the inflammatory process (transplant rejection, autoimmune disease).
  • Very low doses of IL-2/Cs may be administered intravenously (i.v.) or subcutaneously (sc) in order to target active compounds in vivo.
  • Cyclosporine may be replaced by structurally related or unrelated compounds with similar mechanism of action, for example thalidomide or FK506.
  • Methotrexate, and other dihydrofolate reductase inhibitors have been used to treat selected forms of autoimmune and inflammatory diseases and, in combination with Cyclosporine, for prophylaxis of graft-versus-host disease in bone marrow transplantation (Ref 17).
  • the immunosuppressive activity of methotrexate is achieved by inhibiting replication and the functional activity of T-cells (and possibly B-cells), as a result of a relatively selective action on DNA synthesis.
  • the drug is also used for the treatment of severe, active rheumatoid arthritis in adults, and in severe psoriasis.
  • methotrexate The clinical toxicity of methotrexate is high, and reflects the standard toxicity of chemotherapy: severe myelotoxicity, mucositis, hepatic fibrosis, cirrhosis, and pulmonary toxicity.
  • methotrexate Administered on a long-term basis, methotrexate, like other antineoplastic drugs, increases the incidence of infections, malignancies, and sterility in the patient.
  • IL-2/methotrexate complex acts in the same way as IL- 2/Cyclosporine complex.
  • the IL-2 drives the methotrexate into activated lymphocytes, which are responsible for a given autoimmune attack, or immune rejection. These are the only cells in the body bearing the high-affinity IL-2 receptor on the membrane. Methotrexate will inactivate only these T- lymphocytes, by blocking DNA synthesis in the cells (oligoclonal immunosuppression) through intracellular dihydrofolate reductase inhibition.
  • Low dose IL-2 means low dose methotrexate.
  • methotrexate is maintained within the lymphocytes targeted by the system, but the plasma concentration of the whole complex, or of free methotrexate, is practically undetectable.
  • Intracellular nucleophiles such as glutathione, cleave the prodrug azathioprine to mercaptopurine.
  • This purine analogue is subsequently converted into mercaptopurine-containing nucleotides that exert effects on the synthesis and utilisation of precursors of RNA and DNA (Ref 17).
  • Azathioprine has been one of the most important first generation immunosuppressants (combined with prednisone) used to sustain transplants. It has also been used for the treatment of some autoimmune diseases, such as severe and refractory rheumatoid arthritis.
  • this potent antiblastic compound i.e. its lack of specificity towards immune cells
  • results in high toxicity including myelotoxicity (leukopenia and thrombocytopenia), nausea, vomiting, hepatic veno-occlusive disease, and toxicity at the germinal lineage (hypo-amenorrhea and hypo- azoospermia).
  • the prodrug azathoprine is driven only into activated lymphocytes which bear the high affinity receptor for the cytokine IL-2.
  • activated lymphocytes which bear the high affinity receptor for the cytokine IL-2.
  • These cells mainly T-cell lineage
  • the active compound mercaptopurine reach a pharmacological concentration, and be able to block the cell in exerting oligoclonal immunosuppression.
  • lntcrleukin-2/antitumour antibiotics actinomycin D, daunorubicin, doxorubicin, bleomycin and all related compounds.
  • This therapeutic complex includes the most potent antitumour agents (antiblastic drugs) widely used in the treatment of a number of malignancies.
  • the intracellular mechanisms of action include an interaction with DNA and RNA at several molecular levels, resulting in cell death when the intracellular concentration overcomes natural mechanisms of DNA- repair and cell recovery. (Ref 17).
  • the total amount of active compound (the antitumour antibiotic) will be captured exclusively by activated lymphocytes, present in the body as a result of autoimmune disease, or during graft rejection.
  • the intracellular concentration of the active compound in the target cells (predominantly activated T-cells) will reach a pharmacological level which will enable it to block or kill those cells only.
  • the very low plasma concentration of the complex, free IL-2 or free antitumour antibiotic is heavily diluted in litres of volume distribution, with insignificant effects on the non-target systems.
  • Platinum coordination compounds, vinca alkaloids, purine analogues, pyrimidine analogues and corticosteroids can form complexes with IL-2 in a similar fashion to the previously mentioned active agents.
  • Exemplary vinca alkaloids include Vindesine, Vinorelbine and Vinleurosine, amongst others.
  • Interleukin 2/radioactive isotopes product (Rhenium, Yttrium)
  • the active agent linked to IL-2 is a radioactive, cytotoxic isotope.
  • IL-2 radiolabelled with iodine has been used for diagnostic purposes, but it is novel to link cytotoxic isotopes (those isotopes which kill cells using a microscopic high-energy radiation field) to IL-2 in order to drive the radiation field into target cells (T-cells).
  • cytotoxic isotopes such as, etc.
  • T-cells target cells
  • Such specific radioimmunological treatment in vivo may be used to target an immune attack in the inflammatory microenvironment during the autoimmune pathological process, or during rejection of a transplanted organ.
  • the main target is the Human Immunodeficiency Virus (HIV) infection.
  • HIV Human Immunodeficiency Virus
  • AZT Ziidovudine, 3'-azido-3'-deoxythymidine
  • AZT Zidovudine, 3'-azido-3'-deoxythymidine
  • AZT is an active drug against HIV-1 retrovirus.
  • AZT is phosphorylated intracellularly by enzymes to the corresponding deoxynucleoside triphosphate derivative which inhibits viral reverse transcriptase. Its antiviral selectivity is due to its greater affinity for reverse transcriptase than for human DNA polymerases (Ref 16).
  • the concentration of this drug in the body must be maintained at a high level in order to block as much virus replication as possible during a long period of treatment. This leads to mild to severe side-effects due to penetration of AZT into cells other than those in which the HIV virus is naturally present after the infection.
  • the side effects are mainly myelotoxicity and immunosuppression.
  • Interleukin-2/AZT or other anti-HIV compounds
  • the active drug will be captured and internalised only in those lymphocytes bearing high affinity receptors for IL-2, thus reducing the volume of distribution, and the interaction of the active antiretroviral compound with other cells.
  • the intracellular division of the complex of IL-2 (the active compound to promote lymphocyte replication) and the antiretroviral drug (the active compound to block virus replication) provides the basis for a synergistic phenomenon: (a) immunostimulation of lymphocytes which are not HIV infected, with a potential benefit in terms of increasing the general host immune surveillance in these immunocompromised patients (the active antiretroviral compound, which accumulates in the cells, is dangerous for the HIV genome but is rather inert for the cell biochemistry), and (b) in HIV infected lymphocytes, the replication stimulus, provided by IL-2, promotes the replication stimulus for the HIV genome, resulting in increased antiretroviral activity by the antiretroviral drug which is presented into the HIV-infected lymphocytes concurrently.
  • IL-2/antisense fusion products are useful for introducing specific antisense sequences (oligonucleotides) into lymphocytes bearing the IL-2 receptor.
  • Antisense oligonucleotides are short synthetic single strand nucleotides containing sequences complementary to target mRNA or DNA. It is possible to create an antisense compound which blocks specific DNA or RNA sequences related to the HIV genome. What was hitherto unknown, however, was the means to introduce these particular sequences in vivo.
  • cytokines e.g. IL-2
  • an antisense compound for a given tract of the HIV genome e.g. genome coding for an envelope protein, or for the enzyme transcriptase
  • a pharmacological strategy such as IV administration, for example.
  • IL-2/antisense products may also be used to introduce antisense compounds or antioncogenes into the T- cell lineage affected by neoplastic transformation, where gene mutation, or oncogene hyperexpression is known.
  • the IL-2/active compound fusion products are useful for diseases for which the lymphocyte is mainly involved in tissue damage, and the resultant development of a given disease entity.
  • Interleukin-2 high-affinity receptor-directed immunosuppressive therapy acts pharmacologically, but only on recently activated lymphocytes (particularly T- cells), which bear this structure on the cellular membrane.
  • the activation signal is absent from the surface of resting T-cells and all other non-lymphoid tissues. As such, very low doses of cytokine/immunosuppressive drugs can be targeted.
  • lymphocytes Since the receptor is only transiently expressed during the brief proliferative phase, when lymphocytes respond to antigen stimuli (autologous-antigen in the case of autoimmune diseases, and heterologous- antigens in the case of transplantation), it is possible to achieve selective in vivo immunosuppression, directed solely towards activated lymphocytes (oligoclonal immunosuppression). This pharmacological action is totally different from the general immunosuppression action exerted by conventional immunosuppressive drugs.
  • autoimmune diseases which can benefit from this approach include autoimmune diseases, transplant rejection, HIV- infection, and lymphoproliferative diseases.
  • Autoimmune diseases are a wide variety of disorders with a common pathogenic pathway: immune attack on target organs due to abnormal recognition of tissue antigens, and/or cellular antigens, by the immune system, particularly by T-lymphocytes (17).
  • This immune attack is implemented by a network of T-cell-mediated cytotoxicity, humoral autoimmune antibodies produced by B-lymphocytes, complement activation and consumption, and finally by tissue damage.
  • the central role of the abnormal activation of the T-lymphocytes lineage in all autoimmune diseases is well recognised.
  • the clinical disorders under this heading and their target organs include the following:
  • Psoriasis > skin/joints/viscera 20.
  • Sarcoidosis > lung/viscera/skin
  • CD4 cells a cytotoxic subset of CD4
  • T-cells are the dominant T-cell phenotype in the target tissues. T-cells express several activation markers.
  • autoimmune disease is generally less severe in AIDS patients who have CD4 cytopenia. Most autoimmune diseases are treated by attempting to reduce the function of the immune system using immunosuppressive and anti-inflammatory drugs. This therapeutic strategy is conducted in a non-specific way, resulting at times in iatrogenic toxicity and a failure to control the overall disease process.
  • Lymphocytes responsible for the acute phase of a given autoimmune attack, all bear the high-affinity IL-2 receptor on the membrane. They are antigen-activated, or cytokine-activated, lymphocytes with a high avidity for IL-2.
  • IL-2/ immunosuppression products enables the use of IL-2 as the vector of pharmacologically active drugs to exert immunosuppression.
  • the IL- 2/immunosuppressant products selectively bind to, and interact with, only those cells bearing the high- affinity receptor of IL-2. This means that immune cells, responsible for tissue damage and disease progression, are inactivated selectively, potentially curing patients with chronic diseases, or reducing their relapse rate.
  • IL-2 used alone at low or very low doses, has already been shown to be totally safe, and can be administered for long periods.
  • Immunosuppressive drugs used alone at ultra low concentrations, have no efficacy (or toxicity). However, linked together, the two compounds achieve high concentrations only where needed (intracellularly).
  • Recombinant proteins for example recombinant IL-2 and other recombinant cytokines and growth factors, usually have low immunogenicity and good tissue distribution. After parenteral administration, every tissue compartment in the body is exposed, including all lymphocytes (circulating lymphocytes, lymphocytes in the tissues, and lymphocytes in the lymph nodes).
  • the acute or chronic rejection of a transplanted organ is related to heterologous antigens (antigen specific to the donor transplanted organ(s)) presenting to host T-cells. Following antigen presentation and recognition, immune cells enter into a proliferative phase, during which the high-affinity receptor for IL-2 is expressed. This leads to activation of the cytotoxic process, and to damage and subsequent failure of the transplanted organ.
  • IL-2 as a vector to target immunosuppressive drugs achieves longevity of transplanted organs without the associated toxicity of conventional immunosuppressive therapy (acute, delayed, and long term).
  • Allogeneic bone marrow transplantation is used to treat and cure leukemias (both lymphoid and myeloid), thalassemia, and solid tumours.
  • the products of the invention have the potential to reduce the incidence of Graft-Versus-Host-Disease (GVHD), which is the reaction of the donor immune system against tissue antigens of the host, without compromising the global immune-system (of graft origin).
  • GVHD Graft-Versus-Host-Disease
  • IL-2/AZT fusion product or IL-2/antiretroviral analogue, or IL-2/antisense specific to HIV-genome fraction
  • the anti-retroviral compound is introduced into the cytoplasm of HIV-infected lymphocytes (CD4 cells), leading to a selective destruction of infected cells, without impacting on the normal reactive lymphocytes which are stimulated.
  • Lvmphoproliferative diseases Lvmphoblastic leukaemia and lymphomas
  • IL-2/cytotoxic fusion complex it is possible to selectively kill the neoplastic lymphoid lineage expressing the high-affinity IL-2 receptor, without inducing any critical systemic toxicity on non-lymphoid compartments.
  • Products containing growth factors or cytokines other than IL-2 may be used in the therapies described below:
  • TNF- ⁇ has as its target cells macrophages and osteoclasts.
  • TNF- ⁇ /blocking compound products may be used to insert into macrophages a blocking compound (which blocks cellular function and/or kills the cell).
  • a blocking compound which blocks cellular function and/or kills the cell.
  • Such products potentially provide an important tool in some pathological conditions, e.g. advanced solid cancers where macrophage hyperstimulation and activation is responsible for cachexia and tumour progression, monocyto-macrophage neoplasms (e.g. histiocytosis), transplant rejection and GVHD, autoimmunity, and neurological degenerative diseases (the TNF receptor in its extracellular domain is similar to nerve Growth Factor receptor).
  • M-CSF macrophage colony stimulating factor
  • M-CSF is also responsible for microglial proliferation in the CNS.
  • Other potential applications are therefore in some degenerative diseases of the CNS, such as Alzheimer's syndrome, and in bone diseases.
  • IFN/active compound may be used to modify the function of activated lymphocytes, macrophages, endothelial cells and fibroblasts, or to incapacitate them in different pathological conditions, such as in HIV-infection (AIDS), and fibroblast-related diseases such as scleroderma.
  • HIV-infection HIV-infection
  • fibroblast-related diseases such as scleroderma.
  • FGF products include their use as antiangiogenic factors in solid cancers, and to block hyperactivation of fibroblasts in scleroderma.
  • the invention enables the preparation of FGF products capable of acting as an antagonist in relation to the cell types listed earlier in this specification as having FGF high affinity receptor when activated.
  • IFG/antiblastic products may be used to treat breast cancer. Due to the presence of the high affinity receptor in CNS (neuroglia), it could also be used in some degenerative neurological disorders.
  • TGF ⁇ products have applications similar to those of FGF and IFG fusion products.
  • GM-CSF/active compound fusion products may be used to selectively kill myeloid blasts responsible for myeloid leukemias.
  • G-CSF products have similar pharmacological activity to the GM-CSF products, but bind to a different high-affinity receptor present only in multipotent stem cells in the bone marrow.
  • Epo fusion products may be used for diseases such as polycythemia and erythroleukemia, for example.
  • Epo/gene sequence fusion products in which the DNA fraction is the normal gene for haemoglobin beta- chain, may be used for introducing the normal gene into the erythroid lineage in patients affected by beta- Thalassemia.
  • the abnormal gene coding for a non-functional haemoglobin beta- chain
  • the insertion of the normal gene, through the Erythropoietin vector, selectively into the bone marrow erythroblastic lineage, represents true in vivo gene-therapy, to potentially cure patients with this disease.
  • the same consideration applies to another genetic haemoglobin disease: sickle cell anaemia.
  • IL-6/fusion products may be used to block cells, having IL-6 high affinity receptors, which are involved in multiple myeloma, osteoclastic hyperactivation (metastasis to the bone), cancer-related bone lesions and osteoporosis.
  • CTX denotes a cytotoxin
  • Epo/CTX in erythroleukemia (Di Guglielmo Syndrome, also known as M6 Leukemia in FAB classification)
  • CML Chronic Myeloid Leukemia
  • AML Acute Myeloid Leukemia
  • M-CSF/CTX in Wegener's Disease, Granulomatosis, Inflammatory Breast Cancer, Giantcellular vasculitis, Sarcoidosis, histiocitic necrotizing lymphoadenitis (Kikuchi's disease)
  • GM-CSF or G-CSF (or) SCF (or) IL-3/CTX in Myelodisplastic Syndromes (MDS)
  • IGF-1/CTX in breast cancer 1.
  • TGF/CTX in malignant transformations of the bone osteosarcoma, chondrosarcoma, fibrosarcoma
  • fibrodysplastic syndromes sclerodermia
  • TGF/CTX in anti-angiogenesis adenocarcinomas
  • Growth factor fusion products may be used as active vectors in targeting genes.
  • the same growth factors are as above considered, plus lnterleukin-2.
  • a critical point is the fact that these vectors are not only active as transporters of genes, but also promote the rearrangement of DNA, in addition to opening DNA chains in target cells. They are therefore ideal for integrating genes both in vitro and in vivo. No other system available has a comparable bi-modal activity, and without the associated risks of viruses (used currently as vectors).
  • Suitable fusion products and disease targets include:
  • Epo/Hb-beta-gene in Thalassemia 2. Epo/SS-wild gene is Sickle Cell Anemia (or Sickle Cell- Disease)
  • IL-2 or IL-3 (or) GM-CSF/functional genes in congenital immunodeficiencies (usually these immunodeficiencies are inherited as poligenic defects: severe combined immunodeficiencies, Di George's syndrome, Nezelof s syndrome, Ataxia-teleangiectasia, X-linked gammaglobulinemia)
  • Lysosomal storage diseases include most of the lipid storage disorders, the mucopolysaccharidoses and glycoprotein storage diseases which are characterised by mono-enzymatic defects (beta-galactosidase, beta-glucocerebrosidase deficiency in Gaucher's disease, alpha-fucosidase deficiency in Fucosidosis, ceramidase deficiency in Farber's disease and hexosaminidase-A deficiency in Tay-Sachs syndrome). All these serious congenital conditions may have their onset in infantile, juvenile and adult age.
  • M-CSF/wild gene coding for a functional enzyme selected on the basis of the specific deficiency once integrated into macrophages and transcripted into protein, could compete with the nonfunctional protein and repair the defect in vivo.
  • the active agent and the cytokine or growth factor, or its equivalent are suitably linked using a multifunctional (e.g. bifunctional) linker which reacts with respective functional groups on the active agent and the peptide hormone (or equivalent).
  • a linker-chelator may be used, which forms a covalent bond with the cytokine or growth factor or its equivalent, and chelates the isotope.
  • the two constituent parts are linked by an intracellularly cleavable link. In other embodiments, the link is intracellularly stable.
  • linkers are multifunctional, and especially bifunctional compounds capable of reacting with at least two polypeptide molecules.
  • acid-cleavable reagents for interlinking two polypeptides.
  • Such acid-cleavable linker reagents based on orthoester, acetal and ketal functionalities, have been described previously (Ref 18), and are bifunctional compounds whose hydrolytic rate constants increase as the pH decreases.
  • the crosslinkers react with the proteins via heterobifunctional groups (e.g. maleimide or N-hydroxysuccinimide ester) or homobifunctional groups (e.g. bis-maleimide or bis-succinimidyl).
  • cross-linking agents which may be used are:
  • Disuccinimidyl suberate This is a homo-bifunctional cross-linking reagent, containing the N hydroxy succinimide (“NHS”) ester reactive group, which is reactive towards amino groups.
  • the chain of the cross-linking reagent is non-cleavable.
  • the chain of the cross- linking reagent is cleavable.
  • Succinimidyl 6-[3-(2-pyridylthio)-propionamido] hexanoate This is a hetero-bifunctional cross- linking reagent, containing the pyridyldithio and NHS ester reactive groups, which are reactive towards sulfhydryl and amino groups.
  • the chain of the cross-linking reagent is cleavable.
  • Products in which the proliferatively active moiety (especially cytokine or growth factor) and a biologically active agent are acid-cleavably linked benefit from the potential advantage that the product is cleaved in the endosome to release the active agent in free form.
  • the free agent will potentially be more efficacious in its intracellular action than the linked agent.
  • nucleotide (DNA or RNA) active agents for example for gene targeting, cytokines or growth factors can be linked covalently to the nucleotide.
  • the resultant- product may be mixed with the nucleotide to form a protein/DNA complex.
  • R -(CH 2 ) 6 -, -(CH 2 ) 2 -0 2 C-(CH 2 ),-C0 2 -(CH 2 ) 2 -, -CH 2 -S-CH 2 -, -(CH 2 ) 2 - S-(CH 2 ) 2 - or -(CH 2 ) 2 -S-S-(CH 2 ) 2
  • linker-chelates are reacted with the cytokine or growth factor, or its functional equivalent, and then used to chelate a radioisotope.
  • Quadri et al (Ref 21) describe the preparation of stable and labile linkages between polypeptides (antibodies) and chelators.
  • the chelator used was DTPA (diethylene triaminepentaacetic acid).
  • ABDTPA derivative aminobenzyl-DTPA
  • the amino group used to couple the DTPA with a suitable linker was prepared.
  • labile linkers ethylene glycol bis (succinimidylsuccinate) (EGS) and disuccinimidyl tartarate (DST) are used.
  • EGS or DST are mixed, e.g. in equimolar ratio, with ABDTPA, in an anhydrous solvent such as DMSO.
  • the polypeptide suitably in anhydrous solvent (e.g. DMSO) is added to the resultant linker-chelator to form the polypeptide-linker-chelator molecule.
  • anhydrous solvent e.g. DMSO
  • the EGS or DST in the preceding procedure is replaced by the relatively stable hydrocarbon linker DSS (disuccinimidylsuccinate).
  • DSS disuccinimidylsuccinate
  • Quadri is to react ABDTPA with thiophosgene (80% solution in CHC1 2 ) to make isothiocyanatobenzyl-
  • ITCB-DTPA DTPA
  • Linkers suitable for conjugating cytokines and growth factors to biologically active agents are obtainable from Pierce & Warner (UK) Limited, 44 Upper Northgate Street, Chester CHI 4EF, UK, whose literature provides further information.
  • the IL-2 and other cytokines or growth factors may be administered parenterally, in an amount of from 10.000 - 1.000.000 International Units, and suitably by intravenous, intramuscular or subcutaneous injection (less than 1 ⁇ g to 0.1 mg of recombinant protein), to give very low plasma concentrations.
  • the plasma IL-2 concentrations may be close to the dissociation constant (KD) of the concentration of IL-2 that saturates 50% of the IL-2 high-affinity receptor isoform.
  • KD dissociation constant
  • this range of dose is generally without systemic adverse side effects.
  • the products of the invention may be formulated as human or veterinary pharmaceutical formulations in practice comprising a pharmaceutically acceptable diluent carrier or excipient.
  • the formulations may be in the form of solutions or suspensions.
  • the formulations are suitable for parental (e.g. iv or sc) administration but, oral formulations are not excluded.
  • the invention provides a product comprising a biologically active agent linked to a moiety which is a peptide hormone, which has a high affinity receptor, or is a molecule functionally equivalent to the peptide hormone in relation to the high affinity receptor.
  • the peptide hormones include cytokines and growth factors.
  • molecules comprising a domain functionally equivalent to a growth factor (e.g. all or part of a native growth factor) and a cytotoxin domain.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

On décrit un produit comprenant une fraction proliférative active, plus spécifiquement une cytokine ou un facteur de croissance ayant un récepteur à haute affinité, qui est lié(e) à un agent biologiquement actif qui lui-même affecte préférentiellement ou sélectivement des cellules prolifératives. Un promoteur de prolifération actif, par exemple une interleukine active IL-2, est utilisé avec profit pour apporter des espèces intéressantes du point de vue pharmacologique à des cellules dont la prolifération n'est pas désirée. Par exemple, certains médicaments de l'invention régulent ou inhibent la prolifération à l'aide d'une molécule qui contient un promoteur actif de prolifération. L'agent biologiquement actif est généralement sélectionné dans le groupe constitué par des médicaments antiprolifératifs, des composés qui interfèrent avec la synthèse nucléotidique, des radio-isotopes, des séquences de gènes et des séquences nucléotidiques antisens.
PCT/GB1998/003509 1997-11-26 1998-11-25 Produit a activite proliferative utile pour traiter des cellules proliferatives WO1999026660A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
NZ504625A NZ504625A (en) 1997-11-26 1998-11-25 Cytokines or growth factors linked to agents which control cell proliferation and pharmaceutical use
AU12499/99A AU1249999A (en) 1997-11-26 1998-11-25 Proliferatively active product for treating proliferating cells
EP98955771A EP1032427A2 (fr) 1997-11-26 1998-11-25 Produit a activite proliferative utile pour traiter des cellules proliferatives
JP2000521861A JP2001523731A (ja) 1997-11-26 1998-11-25 増殖している細胞を治療するための増殖活性生成物
CA002311733A CA2311733A1 (fr) 1997-11-26 1998-11-25 Produit a activite proliferative utile pour traiter des cellules proliferatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9724838.9 1997-11-26
GBGB9724838.9A GB9724838D0 (en) 1997-11-26 1997-11-26 Compositions

Publications (2)

Publication Number Publication Date
WO1999026660A2 true WO1999026660A2 (fr) 1999-06-03
WO1999026660A3 WO1999026660A3 (fr) 1999-10-14

Family

ID=10822573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/003509 WO1999026660A2 (fr) 1997-11-26 1998-11-25 Produit a activite proliferative utile pour traiter des cellules proliferatives

Country Status (8)

Country Link
EP (1) EP1032427A2 (fr)
JP (1) JP2001523731A (fr)
AU (1) AU1249999A (fr)
CA (1) CA2311733A1 (fr)
GB (1) GB9724838D0 (fr)
NZ (1) NZ504625A (fr)
WO (1) WO1999026660A2 (fr)
ZA (1) ZA9810759B (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074724A2 (fr) * 1999-06-03 2000-12-14 Bioinnovation Limited Produits de therapie genique
US7517887B2 (en) * 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
US7868011B2 (en) 2003-04-09 2011-01-11 General Atomics Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
US8168643B2 (en) 2003-04-09 2012-05-01 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
EP2683395B1 (fr) 2011-03-11 2018-08-01 Assistance Publique - Hôpitaux de Paris Utilisation d'il-2 à faible dose pour le traitement de troubles du diabète de typ i
US10765723B2 (en) 2011-03-11 2020-09-08 INSERM (Institut National de la Santé et de la Recherche Médicale Use of low dose IL-2 for treating autoimmune—related or inflammatory disorders

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0318948A2 (fr) * 1987-12-02 1989-06-07 Neorx Corporation Immunoconjugués clivables pour la délivrance et libération d'agents sous forme naturelle
EP0398305A2 (fr) * 1989-05-17 1990-11-22 Bristol-Myers Squibb Company Conjugés d'anthracycline comportant un nouvel agent de liaison et méthodes pour leur production
EP0510949A2 (fr) * 1991-04-23 1992-10-28 Sangstat Medical Corporation Conjugués cytomodulateurs constants de pair liants spécifiques
WO1993006847A1 (fr) * 1991-10-07 1993-04-15 Genentech, Inc. Utilisation d'interferon-gamma dans le traitement d'infections chez les receveurs de greffe
EP0624377A2 (fr) * 1993-05-14 1994-11-17 Bristol-Myers Squibb Company Conjugués antitumoraux divables pour enzyme lysosomiales
WO1995027732A2 (fr) * 1994-04-08 1995-10-19 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Ligands et molecules chimeriques a permutation circulaire

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0318948A2 (fr) * 1987-12-02 1989-06-07 Neorx Corporation Immunoconjugués clivables pour la délivrance et libération d'agents sous forme naturelle
EP0398305A2 (fr) * 1989-05-17 1990-11-22 Bristol-Myers Squibb Company Conjugés d'anthracycline comportant un nouvel agent de liaison et méthodes pour leur production
EP0510949A2 (fr) * 1991-04-23 1992-10-28 Sangstat Medical Corporation Conjugués cytomodulateurs constants de pair liants spécifiques
WO1993006847A1 (fr) * 1991-10-07 1993-04-15 Genentech, Inc. Utilisation d'interferon-gamma dans le traitement d'infections chez les receveurs de greffe
EP0624377A2 (fr) * 1993-05-14 1994-11-17 Bristol-Myers Squibb Company Conjugués antitumoraux divables pour enzyme lysosomiales
WO1995027732A2 (fr) * 1994-04-08 1995-10-19 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Ligands et molecules chimeriques a permutation circulaire

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BUKOWSKI R. M.: "Natural history and therapy of metastatic renal cell carcinoma. The role of interleukin-2" CANCER, vol. 80, no. 7, 1 October 1997 (1997-10-01), pages 1198-1220, XP002097613 *
KONIGSBERG PJ ET AL: "The development of IL-2 conjugated liposomes for therapeutic purposes." BIOCHIM BIOPHYS ACTA, MAR 13 1998, 1370 (2) P243-51, XP002110538 NETHERLANDS *
MATOS DA SILVA A. C. ET AL: "Outpatient therapy with aldesleukin after autologous bone marrow transplantation" AM J. HEALTH-SYST PHARM, vol. 53, 15 July 1996 (1996-07-15), pages 1722-1727, XP002097614 *
Proleukin (aldesleukin) CHIRON. January 1998 Prescribing information (United States) XP002110539 *
SUNDIN D. J. ET AL: "Aldesleukin therapy in HIV infected patients" AM J. HEALTH-SYST PHARM, vol. 55, 15 July 1998 (1998-07-15), pages 1520-1523, XP002097615 *
SUTHERLAND F. ET AL: "Effects of cyclosporin on C57BL/6 splenocytes before and after culture with high-dose recombinant interleukin-2: implications for immunosuppression with cyclosporin" CANCER IMMUNOL IMMUNOTHER, vol. 31, 1990, pages 312-320, XP002097616 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074724A2 (fr) * 1999-06-03 2000-12-14 Bioinnovation Limited Produits de therapie genique
WO2000074724A3 (fr) * 1999-06-03 2001-07-12 Bioinnovation Ltd Produits de therapie genique
US7517887B2 (en) * 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
US7868011B2 (en) 2003-04-09 2011-01-11 General Atomics Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
US8168643B2 (en) 2003-04-09 2012-05-01 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
EP2683395B1 (fr) 2011-03-11 2018-08-01 Assistance Publique - Hôpitaux de Paris Utilisation d'il-2 à faible dose pour le traitement de troubles du diabète de typ i
EP3443979B1 (fr) 2011-03-11 2020-05-27 Assistance Publique - Hôpitaux De Paris Régime posologique d'il-2 pour le traitement du lupus érythémateux systémique
US10765723B2 (en) 2011-03-11 2020-09-08 INSERM (Institut National de la Santé et de la Recherche Médicale Use of low dose IL-2 for treating autoimmune—related or inflammatory disorders
US11559566B2 (en) 2011-03-11 2023-01-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of low dose IL-2 for treating autoimmune-related or inflammatory disorders

Also Published As

Publication number Publication date
GB9724838D0 (en) 1998-01-21
ZA9810759B (en) 2000-05-25
NZ504625A (en) 2002-12-20
CA2311733A1 (fr) 1999-06-03
EP1032427A2 (fr) 2000-09-06
AU1249999A (en) 1999-06-15
WO1999026660A3 (fr) 1999-10-14
JP2001523731A (ja) 2001-11-27

Similar Documents

Publication Publication Date Title
US7514073B2 (en) Therapeutic use of interleukin-2 mutants
US7833976B2 (en) Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
Asano Human granulocyte colony-stimulating factor: its basic aspects and clinical applications
JPH10513440A (ja) 化学的に修飾したインターフェロン
EP1032427A2 (fr) Produit a activite proliferative utile pour traiter des cellules proliferatives
CA2056555A1 (fr) Agent immunostimulant renfermant de l'interleucine-2 et de la 5'-desoxy-5-fluoro-uridine
Garnick et al. Clinical promise of new hematopoietic growth factors: M-CSF, IL-3, IL-6
CA2157785A1 (fr) Compositions pharmaceutiques a base d'un recepteur d'interleukine-4 soluble et interleukine-4
WO2000074724A2 (fr) Produits de therapie genique
WO2000009150A2 (fr) Cytokines et recepteur de cytokines, agoniste, antagoniste et/ou combinaison d'anticorps a usage therapeutique
Thomas et al. Biological approaches to cancer therapy
Edmonson et al. Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas?
KR102680146B1 (ko) 신규한 면역 활성 인터루킨 2 아날로그 결합체 및 이의 제조 방법
EP3872084A1 (fr) Peptides à base d'épi-x4 et leurs dérivés
WO2004096254A2 (fr) Compositions et procedes pour le traitement des tumeurs
Niskanen Hematopoietic growth factors in clinical hematology
JPH05117163A (ja) 前胸腺細胞の成熟のための医薬製剤
WO1993025228A1 (fr) Cytotoxines specifiques contre les cellules porteuses du recepteur du facteur stimulant les colonies de macrophages de granulocytes (gm-csf)
Tong et al. Site-specific pegylated IL2 mutein with biased IL2 receptor binding for cancer immunotherapy
KR20240099117A (ko) 신규한 면역 활성 인터루킨 2 아날로그 결합체 및 이의 제조 방법
KR20140130705A (ko) 체강액 저류 억제제
CA2198919A1 (fr) Modification graduelle, super-agonistes et antagonistes de peptides et de proteines-signaux
CA1303986C (fr) Action anti-proliferative des arn double brin sur les tumeurs
Schrader et al. T-cell-lymphokines and the production and function of accessory cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 12499/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 504625

Country of ref document: NZ

ENP Entry into the national phase in:

Ref document number: 2311733

Country of ref document: CA

Ref country code: CA

Ref document number: 2311733

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998955771

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998955771

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998955771

Country of ref document: EP